Grand View Research found that North America accounts for the largest revenue share, with more than 75% of the GLP-1 agonists market. While other alternative obesity interventions exist, including ...

Broadcom stock fell despite record AI revenue growth as investors weigh margin pressure, valuation risks and future demand.

So, Regeneron's revenue rose 1.9% from $3.68 billion in Q2 2025 to $3.75 billion, beating consensus estimate by $160 million ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 14 Best US Stocks to Buy for Long Term. On December 4, ...

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Regeneron Pharmaceuticals, Inc. REGN announced a collaboration agreement with private company Tessera Therapeutics, Inc. for ...

Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 15 years by 11.76% on an annualized basis producing an average annual return of 23.85%. Currently, Regeneron ...

Shares of Regeneron Pharmaceuticals REGN have gained 21.5% year to date compared with the industry’s growth of 10.2%. The ...

Sales of Regeneron Pharmaceuticals' Eylea have declined over the past few quarters due to competition. However, the company launched a new formulation of the medicine that just earned another label ...

Regeneron Pharmaceuticals is a leading biotech focused on gene editing. While the S&P 500 has dipped lower in November, Regeneron stock has climbed steadily higher. Despite its recent rise, Regeneron ...